FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Persistent Atrial FibrillationLongstanding Persistent Atrial FibrillationAtrial Fibrillation, PersistentArrhythmias, Cardiac
Interventions
DEVICE

Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter

"Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL)."

Trial Locations (1)

32545

Herz-und Diabeteszentrum NRW (Clinic of Ruhr University of Bochum), Bad Oeynhausen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ablacon, Inc.

INDUSTRY

NCT06260670 - FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation | Biotech Hunter | Biotech Hunter